 |
|
Thyroid Suppression and Medical Ablation for Differentiated Thyroid Cancer
John T. Dunn, MD
Arch Otolaryngol Head Neck Surg. 1986;112(11):1207-1209.
Abstract
• Patients with thyroid cancer benefit from treatment with exogenous thyroid hormone for two reasons: (1) it provides adequate levels of thyroid hormone to peripheral tissues, and (2) it reduces the level of thyrotropin, which may be an important growth factor in patients with differentiated malignant neoplasms. The use of radioactive iodine for thyroid cancer is highly controversial. Its most appropriate applications are in follicular cancers, in older patients, and in distant functioning metastases. Its value in papillary cancer is questionable, particularly in young patients. There is a great need for effective basic and clinical research on the natural course of differentiated thyroid cancer and the effects of specific therapies.
(Arch Otolarygnol Head Neck Surg 1986;112:1207-1209)
Author Affiliations
From the Division of Endocrinology and Metabolism, Department of Medicine, University of Virginia Medical Center, Charlottesville.
Footnotes
Accepted for publication Aug 14, 1986.
Read before the American Society for Head and Neck Surgery, Palm Beach, Fla, May 7, 1986.
Reprint requests to the Division of Endocrinology, Department of Medicine, Box 511, University of Virginia Medical Center, Charlottesville, VA 22908 (Dr Dunn).
 CiteULike  Connotea  Del.icio.us  Digg  Reddit  Technorati  Twitter
What's this?
THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES
Thyroglobulin Assays in the Postoperative Management of Differentiated Thyroid Cancer
Harley et al.
Arch Otolaryngol Head Neck Surg 1988;114:333-335.
ABSTRACT
Thyroid Suppression and Radioiodine Treatment for Differentiated Thyroid Cancer
ROSLER
Arch Otolaryngol Head Neck Surg 1987;113:778-778.
ABSTRACT
|
